Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$2.47 - $3.53 $11,715 - $16,742
-4,743 Reduced 21.51%
17,308 $45,000
Q1 2023

May 15, 2023

SELL
$3.06 - $4.5 $21,557 - $31,702
-7,045 Reduced 24.21%
22,051 $76,000
Q4 2022

Feb 14, 2023

SELL
$2.75 - $4.1 $50,297 - $74,989
-18,290 Reduced 38.6%
29,096 $116,000
Q3 2022

Nov 14, 2022

BUY
$3.0 - $4.78 $142,158 - $226,505
47,386 New
47,386 $142,000

Others Institutions Holding ACXP

About Acurx Pharmaceuticals, Inc.


  • Ticker ACXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,556,600
  • Market Cap $22M
  • Description
  • Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...
More about ACXP
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.